Medios AG, a leading provider of Specialty Pharma in Europe, has announced the appointment of Katrin Neuffer (49) as Director Investor Relations & Communications, effective immediately. In her new role, Neuffer will oversee the company's communications with investors, analysts, the media, and the public, succeeding Claudia Nickolaus, who has led the department and will now hand over leadership.
Neuffer brings extensive experience in capital markets communications, with a career spanning approximately 20 years. After starting at an Investor Relations agency, she served as Head of Investor Relations & Corporate Communications at SDAX-listed Wacker Neuson SE from 2007 to 2018, guiding the company through its IPO and establishing it as a consistently attractive investment. She also led the Strategy and Sustainability departments there. Subsequently, she headed an international 20-member team as Vice President Investor Relations & Corporate Communications and Marketing at the Exyte Group (formerly M+W Group), where she was responsible for preparing an IPO with a targeted market capitalization of more than EUR 2 billion. Since 2020, Neuffer has worked as an independent consultant, advising publicly listed companies on investor relations, IPO preparation, and crisis and restructuring communications.
Claudia Nickolaus, the outgoing head, played a pivotal role in building and shaping Medios' Investor Relations activities, from financial reporting and ESG communications to the company's first Capital Markets Day in 2022. Prior to joining Medios, she held senior Investor Relations positions at publicly listed companies, including Merck KGaA.
Thomas Meier, CEO of Medios AG, commented: "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media. On behalf of the Company, I would like to express my sincere thanks to Claudia Nickolaus: Over many years, she shaped Medios' capital markets communications with tremendous dedication, a high level of professionalism, and personal reliability. She deserves our sincere gratitude for this."
This leadership change comes at a critical time for Medios as it prepares for several key events in the 2026 financial year. The company will release its Half-Year Financial Report on August 12, 2026, and will participate in the Berenberg and Goldman Sachs 15th German Corporate Conference in München from September 21 to 23. On September 28 and 29, Medios will host its Capital Markets Day, followed by the Quarterly Statement as of September 30, 2026, on November 10. These events will provide opportunities for the new leadership to engage with the investment community and communicate the company's strategic direction.
Medios AG is Germany's first listed specialty pharmaceutical company, with shares (ISIN: DE000A1MMCC8) listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. With locations in Germany, the Netherlands, Belgium, and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine to make the most innovative therapies available to everyone. More information about individualized medicine can be found at https://app.medios.group/en/individualizedmedicine.
The appointment of Neuffer signals Medios' commitment to strengthening its capital markets presence and enhancing transparency with stakeholders. Her track record in guiding companies through IPOs and strategic transformations will be invaluable as Medios continues to grow and adapt in the evolving specialty pharma sector.
